Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Captopril vs Evolocumab (Repatha): Evolocumab (Repatha) has the stronger overall evidence (4.5 vs 3.5/10); they're alternatives for support heart health — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Evolocumab (Repatha) wins 3 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (1)
Outcomes where both Captopril and Evolocumab (Repatha) have evidence — compare verdict strength side-by-side.
Off-label longevity use mirrors low antihypertensive dosing (captopril is short-acting; longer-acting ACE inhibitors like lisinopril/ramipril are often used) under a clinician. Not an approved longevity regimen; blood pressure and potassium should be monitored.
any
Oral tablet (or a longer-acting ACE inhibitor)
Standard approved dosing is 140 mg subcutaneously every 2 weeks OR 420 mg subcutaneously once monthly, under a clinician. A prescription drug; this is informational, not a recommendation.
any
Subcutaneous prefilled autoinjector (evolocumab)
Unknown in humans
Months to years
Years
Throughout use
Weeks
Months to years
Weeks
Throughout use
Angiotensin Converting Enzyme (ACE) Inhibitor Extends Caenorhabditis elegans Life Span.
PLoS genetics (2016) · Animal
ACE inhibition extended lifespan in the worm C. elegans
The ACE inhibitor captopril inhibits ACN-1 to control dauer formation and aging.
Development (Cambridge, England) (2024) · Animal
Captopril specifically inhibits the worm ACE homolog ACN-1
Control of aging by the renin-angiotensin system: a review of C. elegans, Drosophila, and mammals.
Frontiers in pharmacology (2022) · Review
Review framing RAS/ACE modulation as a conserved aging pathway
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
The New England journal of medicine (2017) · Rct · n=27564
FOURIER randomized ~27,564 patients with atherosclerotic cardiovascular disease on statin therapy
Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease.
Circulation (2022) · Open label
FOURIER-OLE: open-label extension following patients on long-term evolocumab
Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.
JAMA (2016) · Rct
GLAGOV randomized statin-treated patients to evolocumab or placebo with serial intravascular ultrasound
Evolocumab (Repatha) has a higher evidence score (4.5/10 vs 3.5/10) and wins in 3 of 3 categories.
For support heart health, Evolocumab (Repatha) has a higher relevance score (80 vs 62).
No known interactions between Captopril and Evolocumab (Repatha) have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.